<html xmlns:v="urn:schemas-microsoft-com:vml"
xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:m="http://schemas.microsoft.com/office/2004/12/omml"
xmlns="http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=ProgId content=Word.Document>
<meta name=Generator content="Microsoft Word 14">
<meta name=Originator content="Microsoft Word 14">
<link rel=File-List href="PMC%202361658%20Table%202_files/filelist.xml">
<link rel=Edit-Time-Data href="PMC%202361658%20Table%202_files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Wilson, Valentine A.</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>Wilson, Valentine A.</o:LastAuthor>
  <o:Revision>14</o:Revision>
  <o:TotalTime>43</o:TotalTime>
  <o:Created>2016-06-21T16:01:00Z</o:Created>
  <o:LastSaved>2016-06-28T14:18:00Z</o:LastSaved>
  <o:Pages>2</o:Pages>
  <o:Words>4358</o:Words>
  <o:Characters>24847</o:Characters>
  <o:Company>Leidos</o:Company>
  <o:Lines>207</o:Lines>
  <o:Paragraphs>58</o:Paragraphs>
  <o:CharactersWithSpaces>29147</o:CharactersWithSpaces>
  <o:Version>14.00</o:Version>
 </o:DocumentProperties>
</xml><![endif]-->
<link rel=themeData href="PMC%202361658%20Table%202_files/themedata.thmx">
<link rel=colorSchemeMapping
href="PMC%202361658%20Table%202_files/colorschememapping.xml">
<!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:Zoom>164</w:Zoom>
  <w:TrackMoves>false</w:TrackMoves>
  <w:TrackFormatting/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:DoNotPromoteQF/>
  <w:LidThemeOther>EN-US</w:LidThemeOther>
  <w:LidThemeAsian>X-NONE</w:LidThemeAsian>
  <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SplitPgBreakAndParaMark/>
  </w:Compatibility>
  <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel>
  <m:mathPr>
   <m:mathFont m:val="Cambria Math"/>
   <m:brkBin m:val="before"/>
   <m:brkBinSub m:val="&#45;-"/>
   <m:smallFrac m:val="off"/>
   <m:dispDef/>
   <m:lMargin m:val="0"/>
   <m:rMargin m:val="0"/>
   <m:defJc m:val="centerGroup"/>
   <m:wrapIndent m:val="1440"/>
   <m:intLim m:val="subSup"/>
   <m:naryLim m:val="undOvr"/>
  </m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
  DefSemiHidden="true" DefQFormat="false" DefPriority="99"
  LatentStyleCount="267">
  <w:LsdException Locked="false" Priority="0" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="heading 2"/>
  <w:LsdException Locked="false" Priority="9" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="heading 3"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
  <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 1"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 2"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 3"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 4"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 5"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 6"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 7"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 8"/>
  <w:LsdException Locked="false" Priority="39" Name="toc 9"/>
  <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
  <w:LsdException Locked="false" Priority="10" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Title"/>
  <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
  <w:LsdException Locked="false" Priority="11" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
  <w:LsdException Locked="false" Priority="22" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
  <w:LsdException Locked="false" Priority="20" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
  <w:LsdException Locked="false" Priority="59" SemiHidden="false"
   UnhideWhenUsed="false" Name="Table Grid"/>
  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
  <w:LsdException Locked="false" Priority="1" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 1"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
  <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
  <w:LsdException Locked="false" Priority="34" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
  <w:LsdException Locked="false" Priority="29" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
  <w:LsdException Locked="false" Priority="30" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 1"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 2"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 2"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 3"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 3"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 4"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 4"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 5"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 5"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
  <w:LsdException Locked="false" Priority="60" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="61" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light List Accent 6"/>
  <w:LsdException Locked="false" Priority="62" SemiHidden="false"
   UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="63" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="64" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="65" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="66" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="67" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
  <w:LsdException Locked="false" Priority="68" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
  <w:LsdException Locked="false" Priority="69" SemiHidden="false"
   UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
  <w:LsdException Locked="false" Priority="70" SemiHidden="false"
   UnhideWhenUsed="false" Name="Dark List Accent 6"/>
  <w:LsdException Locked="false" Priority="71" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
  <w:LsdException Locked="false" Priority="72" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
  <w:LsdException Locked="false" Priority="73" SemiHidden="false"
   UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
  <w:LsdException Locked="false" Priority="19" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
  <w:LsdException Locked="false" Priority="21" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
  <w:LsdException Locked="false" Priority="31" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
  <w:LsdException Locked="false" Priority="32" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
  <w:LsdException Locked="false" Priority="33" SemiHidden="false"
   UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
  <w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
  <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
 </w:LatentStyles>
</xml><![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1073786111 1 0 415 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;
	mso-font-charset:0;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-520081665 -1073717157 41 0 66047 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-parent:"";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:minor-fareast;
	mso-bidi-font-family:"Times New Roman";}
h1
	{mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 1 Char";
	mso-margin-top-alt:auto;
	margin-right:0in;
	mso-margin-bottom-alt:auto;
	margin-left:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:1;
	font-size:24.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:minor-fareast;
	font-weight:bold;}
h2
	{mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 2 Char";
	mso-margin-top-alt:auto;
	margin-right:0in;
	mso-margin-bottom-alt:auto;
	margin-left:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:2;
	font-size:18.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:minor-fareast;
	font-weight:bold;}
h3
	{mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-qformat:yes;
	mso-style-link:"Heading 3 Char";
	mso-margin-top-alt:auto;
	margin-right:0in;
	mso-margin-bottom-alt:auto;
	margin-left:0in;
	mso-pagination:widow-orphan;
	mso-outline-level:3;
	font-size:13.5pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:minor-fareast;
	font-weight:bold;}
a:link, span.MsoHyperlink
	{mso-style-noshow:yes;
	mso-style-priority:99;
	color:blue;
	text-decoration:underline;
	text-underline:single;}
a:visited, span.MsoHyperlinkFollowed
	{mso-style-noshow:yes;
	mso-style-priority:99;
	color:purple;
	text-decoration:underline;
	text-underline:single;}
p
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-margin-top-alt:auto;
	margin-right:0in;
	mso-margin-bottom-alt:auto;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:minor-fareast;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:8.0pt;
	font-family:"Tahoma","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:minor-fareast;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 1";
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 2";
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-noshow:yes;
	mso-style-priority:9;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Heading 3";
	font-family:"Times New Roman","serif";
	mso-ascii-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	font-weight:bold;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-style-locked:yes;
	mso-style-link:"Balloon Text";
	font-family:"Tahoma","sans-serif";
	mso-ascii-font-family:Tahoma;
	mso-hansi-font-family:Tahoma;
	mso-bidi-font-family:Tahoma;}
p.p, li.p, div.p
	{mso-style-name:p;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-margin-top-alt:auto;
	margin-right:0in;
	mso-margin-bottom-alt:auto;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:minor-fareast;}
p.msochpdefault, li.msochpdefault, div.msochpdefault
	{mso-style-name:msochpdefault;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-margin-top-alt:auto;
	margin-right:0in;
	mso-margin-bottom-alt:auto;
	margin-left:0in;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Calibri","sans-serif";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:minor-fareast;
	mso-bidi-font-family:"Times New Roman";}
p.msopapdefault, li.msopapdefault, div.msopapdefault
	{mso-style-name:msopapdefault;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-unhide:no;
	mso-margin-top-alt:auto;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	line-height:115%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	mso-fareast-font-family:"Times New Roman";
	mso-fareast-theme-font:minor-fareast;}
span.cit
	{mso-style-name:cit;
	mso-style-unhide:no;}
span.fm-vol-iss-date
	{mso-style-name:fm-vol-iss-date;
	mso-style-unhide:no;}
span.doi1
	{mso-style-name:doi1;
	mso-style-unhide:no;}
span.fm-citation-ids-label
	{mso-style-name:fm-citation-ids-label;
	mso-style-unhide:no;}
span.email-label
	{mso-style-name:email-label;
	mso-style-unhide:no;}
span.kwd-text
	{mso-style-name:kwd-text;
	mso-style-unhide:no;}
span.small-caps
	{mso-style-name:small-caps;
	mso-style-unhide:no;}
span.citation
	{mso-style-name:citation;
	mso-style-unhide:no;}
span.ref-journal
	{mso-style-name:ref-journal;
	mso-style-unhide:no;}
span.ref-vol
	{mso-style-name:ref-vol;
	mso-style-unhide:no;}
span.nowrap
	{mso-style-name:nowrap;
	mso-style-unhide:no;}
.MsoChpDefault
	{mso-style-type:export-only;
	mso-default-props:yes;
	font-size:10.0pt;
	mso-ansi-font-size:10.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	mso-ascii-font-family:Calibri;
	mso-hansi-font-family:Calibri;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;
	mso-header-margin:.5in;
	mso-footer-margin:.5in;
	mso-paper-source:0;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 @list l0
	{mso-list-id:1252813769;
	mso-list-template-ids:-1596535096;}
@list l0:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l0:level2
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l0:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l0:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l0:level5
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:2.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l0:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l0:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l0:level8
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:4.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l0:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:4.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1
	{mso-list-id:1983852457;
	mso-list-template-ids:1202455316;}
@list l1:level1
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1:level2
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:1.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1:level3
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:1.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1:level4
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:2.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1:level5
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:2.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1:level6
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1:level7
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:3.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1:level8
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:4.0in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
@list l1:level9
	{mso-level-number-format:bullet;
	mso-level-text:\F0B7;
	mso-level-tab-stop:4.5in;
	mso-level-number-position:left;
	text-indent:-.25in;
	mso-ansi-font-size:10.0pt;
	font-family:Symbol;}
ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Table Normal";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-priority:99;
	mso-style-parent:"";
	mso-padding-alt:0in 5.4pt 0in 5.4pt;
	mso-para-margin:0in;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext="edit" spidmax="1026"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext="edit">
  <o:idmap v:ext="edit" data="1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=EN-US link=blue vlink=purple style='tab-interval:.5in'>

<div class=WordSection1>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span style='mso-no-proof:yes'><img width=313 height=71
id="_x0000_i1029" src="PMC%202361658%20Table%202_files/image001.png"></span><span
style='font-size:12.0pt;font-family:"Times New Roman","serif";mso-no-proof:
yes'><img width=500 height=75 id="_x0000_i1028"
src="PMC%202361658%20Table%202_files/image002.gif" alt="Logo of brjcancer"></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'>Br J Cancer. 2005 Oct 17; 93(8): 949�952. </span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'>Published online 2005 Sep 20. doi:&nbsp; <a
href="http://dx.doi.org/10.1038%2Fsj.bjc.6602790" target="pmc_ext">10.1038/sj.bjc.6602790</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'>PMCID: PMC2361658</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:24.0pt;font-family:"Times New Roman","serif";mso-ansi-language:
EN'>Interaction between the bone morphogenetic proteins and Ras/MAP-kinase
signalling pathways in lung cancer</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'><a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Kraunz%20KS%5Bauth%5D">K S
Kraunz</a>,<sup>1</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Nelson%20HH%5Bauth%5D">H H
Nelson</a>,<sup>2</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Liu%20M%5Bauth%5D">M Liu</a>,<sup>1</sup>
<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Wiencke%20JK%5Bauth%5D">J K
Wiencke</a>,<sup>3</sup> and <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Kelsey%20KT%5Bauth%5D">K T
Kelsey</a><sup>1,*</sup></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none;mso-hide:all;mso-ansi-language:EN'>1</span></sup><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif";display:none;
mso-hide:all;mso-ansi-language:EN'>Department of Genetics and Complex Diseases,
Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none;mso-hide:all;mso-ansi-language:EN'>2</span></sup><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif";display:none;
mso-hide:all;mso-ansi-language:EN'>Department of Environmental Health, Harvard
School of Public Health, 665 Huntington Avenue, Boston, MA 02115, USA</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none;mso-hide:all;mso-ansi-language:EN'>3</span></sup><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif";display:none;
mso-hide:all;mso-ansi-language:EN'>Department of Neurological Surgery,
Laboratory for Molecular Epidemiology, University of California at San
Francisco, San Francisco, CA 94143-0441, USA</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none;mso-hide:all;mso-ansi-language:EN'>*</span></sup><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif";display:none;
mso-hide:all;mso-ansi-language:EN'>Author for correspondence: Email: <a
href="mailto:dev@null">ude.dravrah.hpsh@yeslek</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/">Author information &#9658;</a>
<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/">Article notes &#9658;</a>
<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/">Copyright and
License information &#9658;</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none;mso-hide:all;mso-ansi-language:EN'>Received 2005 May 27; Revised
2005 Jul 25; Accepted 2005 Aug 17.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none;mso-hide:all;mso-ansi-language:EN'><a
href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright</a> 2005,
Cancer Research UK</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'>This article has been <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/citedby/">cited by</a>
other articles in PMC.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;tab-stops:534.0pt'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif";
text-transform:uppercase;mso-ansi-language:EN'>Abstract<span style='mso-tab-count:
1'>������������������������������������������������������������������������������������������������� </span></span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:lime;mso-highlight:
lime;mso-ansi-language:EN'>Bone morphogenetic proteins (BMPs) are an integral
component of the TGF<i>&#946;</i> superfamily, responsible for regulation of
cell proliferation, differentiation, migration and programmed cell death in a
variety of cell types.</span><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";mso-ansi-language:EN'> The BMPs transduce their
signals directly through the SMAD family of proteins but they also have been
reported to interact with the MAPK and Erk pathways. Inactivation of the BMP
pathway genes has been implicated as important in several cancers. Recent work
has shown that <i>BMP3b</i> is epigenetically inactivated in cancer and
suggests that <i>BMP6</i> can be epigenetically inactivated. <span
style='background:yellow;mso-highlight:yellow'>We investigated whether <i>BMP6</i>
is epigenetically
inactivated in cell lines and whether <i>BMP3b</i> and <i>BMP6</i> are
epigenetically inactivated in non-small-cell lung cancer (NSCLC).</span> <span
style='background:yellow;mso-highlight:yellow'>We also studied the relationship
between BMP methylation and <i>k-ras</i> mutation.</span> <span
style='background:yellow;mso-highlight:yellow'>Here, we demonstrate that the <i>BMP3b</i>
and <i>BMP6</i> genes are common targets of epigenetic inactivation in NSCLC,
and that they are significantly more likely to be concurrently inactivated (<i>P</i>=0.009).</span>
<span style='background:yellow;mso-highlight:yellow'>Furthermore, this
coinactivation of <i>BMP3b</i> and <i>BMP6</i> is significantly associated with
mutation of <i>k-ras</i> codon 12 in lung cancer (<i>P</i>=0.003); those with a
<i>k-ras</i> mutation were six times more likely to have concurrent methylation
of these BMP loci.</span> Hence, these data suggest that concurrent
inactivation of the BMP and activation of the Ras signalling pathways are
important in lung carcinogenesis.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'>Keywords: </span></b><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:EN'>bone morphogenetic
proteins, methylation, epigenetic inactivation, <i>k-ras</i> mutation,
non-small-cell lung cancer</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:
EN'>k-ras</span></i><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'> mutation, which leads to aberrant Ras/MAP-K pro-growth
signalling, has been well studied in cancer (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib4">Cunningham and
Weinberg, 1985</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib17">Nelson <i>et
al</i>, 1999</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib8">Huber and
Stratakis, 2004</a>). However, additional signalling pathways are acknowledged
to play important roles in malignant disease, with the bone morphogenetic
protein (BMP) signalling pathway emerging as important in multiple cancers (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib14">Nagatake <i>et
al</i>, 1996</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib20">Tamada <i>et
al</i>, 2001</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib2">Baldus <i>et
al</i>, 2004</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib5">Dai <i>et al</i>,
2004</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib9">Kim
<i>et al</i>, 2004</a>). It is well recognised that the BMP signalling pathways
are crucial for all stages of embryonic development, including regulation of
lung development and airway branching (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib22">Weaver <i>et
al</i>, 1999</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib12">Lu <i>et al</i>,
2001</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib18">Rosendahl
<i>et al</i>, 2002</a>). The BMPs have been shown to be growth inhibitory by
suppressing proliferation (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib5">Dai <i>et al</i>,
2004</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib7">Haudenschild
<i>et al</i>, 2004</a>). They act through upregulation of the cell cycle
proteins p21 and p27 (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib15">Nakamura <i>et
al</i>, 2003</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib3">Brubaker <i>et
al</i>, 2004</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib7">Haudenschild <i>et
al</i>, 2004</a>). The relationship between the TGF<i>&#946;</i>/BMP antigrowth
and Ras/MAP-K progrowth signalling pathways remains unclear, but there is
recent evidence of crosstalk between them (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib10">Kretzschmar <i>et
al</i>, 1997</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib24">Yue <i>et al</i>,
1999</a>; <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib21">Wach
<i>et al</i>, 2001</a>). While BMP-2 stimulation of osteoblasts leads to
activation of Ras (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib16">Nakayama <i>et
al</i>, 2003</a>), in <i>Xenopus</i>, BMP-4-stimulated erythroid
differentiation is inhibited by dominant-negative activation of the Ras pathway
(<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib23">Xu <i>et
al</i>, 1996</a>). SMAD7, one of the inhibitory SMADs of the BMP/TGF<i>&#946;</i>
signalling pathway, has been shown to cooperate with oncogenic Ras to escape
growth arrest (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib11">Liu <i>et al</i>,
2003</a>). While there is experimental evidence of an association between the
BMP signalling proteins and oncogenic Ras, the nature of any interaction of BMP
cytokine inactivation and <i>k-ras</i> mutation has been relatively unexplored
in human tumours. <span style='background:yellow;mso-highlight:yellow'>As a
result of the known importance of BMP signalling in the respiratory tract and
the <i>in vitro</i> evidence of crosstalk between signalling pathways, we
hypothesised that concurrent BMP inactivation and oncogenic <i>k-ras</i>
mutation would be important in non-small-cell lung cancer (NSCLC).</span></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:18.0pt;font-family:"Times New Roman","serif";text-transform:
uppercase;mso-ansi-language:EN'>MATERIALS AND METHODS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif";mso-ansi-language:
EN'>Study population </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:EN'>Eligible
cases consisted of all the newly diagnosed patients with resectable lung cancer
who received treatment at the Massachusetts General Hospital Thoracic Surgery
Service from November 1992 to December 1996 (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib17">Nelson <i>et
al</i>, 1999</a>). All patients involved provided written informed consent in
accordance with the appropriate institutional review boards. Patients with
recurrent disease or nonoperable tumours were excluded. Tumours were
snap-frozen in liquid nitrogen and stored at &#8722;80�C until genomic
preparation. <span style='background:yellow;mso-highlight:yellow'>There were
155 cases with fresh tumour DNA available to be tested for BMP3b and BMP6
methylation.</span> <span style='background:yellow;mso-highlight:yellow'>Demographic
and epidemiologic data, including all of the data on tobacco use and
occupational asbestos exposure, were obtained from a self-administered
questionnaire</span> <span style='background:yellow;mso-highlight:yellow'>completed
by patients and subsequently reviewed by a single reviewer during the
hospitalisation for thoracic surgery.</span> <span style='background:yellow;
mso-highlight:yellow'>Asbestos exposure was defined as having any occupational
asbestos exposure (yes/no), assessed as previously described (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib17">Nelson <i>et
al</i>, 1999</a>).</span></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif";mso-ansi-language:
EN'>Cell culture </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:EN'>Lymphoblastic
WTK1 and HT cells, small-cell carcinoma Shp77 cells, and non-small-cell
carcinoma H322M and A549 cells were maintained in RPMI-1640 medium supplemented
with 10% fetal calf serum. Prostate carcinoma DU145 cells and lung fibroblast
IMR90 cells were maintained in minimum essential media (Eagle's) supplemented
with 10% fetal calf serum. WTK1 cells (2 � 10<sup>5</sup>) in 10&#8201;ml media
were treated with 1&#8201;<i>&#956;</i>l 5-aza-deoxycytadine in PBS or PBS
alone for 3 days and then harvested.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif";mso-ansi-language:
EN'>Reverse transcription PCR </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:EN'>Total RNA
was isolated using Qiagen RNeasy kit. cDNA was synthesised from the RNA using
the SuperScript III kit from Invitrogen. Reverse transcription PCR (RT�PCR)
amplification of the BMP6 cDNA was performed using primers designed with
Primer3. The BMP6 primers used are as follows: 5&#8242;-ACA GCA TAA CAT GGG GCT
TC-3&#8242; (sense) and 5&#8242;-CTC GGG GTT CAT AAG GTG AA-3&#8242;. B-actin
cDNA was amplified using primers supplied with the SuperScript III kit.
Approximately 50&#8201;ng of DNA was used as template. The PCR mixture
contained 10 � PCR buffer, dNTPs (200&#8201;<i>&#956;</i>M of each), primers (1&#8201;<i>&#956;</i>M
of each) and 0.25&#8201;<i>&#956;</i>l TaqGold. cDNA was amplified using an
annealing temperature of 60�C over 35 cycles. PCR product was visualised on an
ethidium bromide-stained agarose gel.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif";mso-ansi-language:
EN'>Methylation-specific PCR </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:EN'>Two sets of primers
specific to the BMP6 promoter region were designed using Primer3 to amplify
bisulphite-modified DNA; one specific for DNA methylated (M) at the promoter
region and the other specific for unmethylated (U) DNA. The primers used are as
follows: (M) 5&#8242;-GGT TTG TTG GGT AGT CGG G-3&#8242; (sense) and GCC CCT
CCC CAA ATC G-3&#8242; (antisense) and (U) 5&#8242;-TTG GGT AGT TGG GTG ATT
GTT-3&#8242; (sense) and 5&#8242;-ACA CCC CTC CCC AAA TCA-3&#8242; (antisense).
Approximately 50&#8201;ng of sodium bisuphfite-modified DNA was used as
template. The PCR mixture contained 10 � PCR buffer, dNTPs (200&#8201;<i>&#956;</i>M
of each), primers (1&#8201;<i>&#956;</i>M of each) and 0.25&#8201;<i>&#956;</i>l
TaqGold. Product was amplified using an annealing temperature of 60�C over 38
cycles. Nontreated and <i>Sss</i>I methylase-treated lymphocytes were used as
controls. PCR products were separated by electrophoresis and visualised by
ethidium bromide staining.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif";mso-ansi-language:
EN'>Statistical analysis </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:EN'>SAS software
was used for statistical analysis. Wilcoxon rank sum test and Fisher's exact
test (or <i>&#967;</i><sup>2</sup> test) were used for continuous and categorical
variables in univariate analysis, respectively. <span style='background:yellow;
mso-highlight:yellow'>Multivariate logistic regression was conducted to
estimate the relationship between methylation of BMPs, k-ras mutation and
covariates that were statistically significant in univariate analysis and that
were important biologically.</span></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:18.0pt;font-family:"Times New Roman","serif";text-transform:
uppercase;mso-ansi-language:EN'>RESULTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif";mso-ansi-language:
EN'>Methylation of <i>BMP6</i> in cell lines </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:EN'>In an effort
to determine whether transcription of the <i>BMP6</i> gene is inhibited by
promoter methylation, we first examined the transcriptional status of <i>BMP6</i>
in cell lines using RT�PCR (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/figure/fig1/"
target=figure>Figure 1A</a>). BMP6 mRNA was absent in WTK1 normal human
lymphoblastoid cells. Following treatment with 5-aza-deoxycytadine, a DNA
methyltransferase inhibitor, transcription was reactivated, demonstrating that
the loss of transcription of <i>BMP6</i> is due to epigenetic inactivation (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/figure/fig1/"
target=figure>Figure 1B</a>). Using primers designed specifically to
differentiate between methylated and nonmethylated DNA at the <i>BMP6</i> gene
promoter, we demonstrated that the WTK1 cells are methylated at the <i>BMP6</i>
gene promoter (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/figure/fig1/"
target=figure>Figure 1C</a>).</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/figure/fig1/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-no-proof:yes;text-decoration:none;text-underline:none'><img border=0
width=100 height=113 id="_x0000_i1027"
src="PMC%202361658%20Table%202_files/image003.gif" alt="Figure 1"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/figure/fig1/"
target=figure>Figure 1</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><i><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'>BMP6</span></i><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif";mso-ansi-language:EN'> is epigenetically
inactivated in cancer cell lines. (<b>A</b>) BMP6 cDNA was amplified using an
annealing temperature of 60�C over 35 cycles with the following primers: 5&#8242;-ACA
GCA TAA CAT GGG GCT TC-3&#8242; (sense) and 5&#8242;-CTC <b>...</b></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif";mso-ansi-language:
EN'>Methylation of <i>BMP3b</i> and <i>BMP6</i> in NSCLC cases </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:EN'>We evaluated
<i>BMP3b</i> and <i>BMP6</i> gene promoter methylation status in 155 NSCLC
cases. In a consecutive case series, we found that 57% (88 out of 155) and 43%
(67 out of 155) of NSCLCs were methylated at the <i>BMP3b</i> and <i>BMP6</i>
gene promoters, respectively. Since both BMP3b and BMP6 signal in the same
pathways, we tested whether there was a relationship between inactivation of
the two genes. We found that 52% (46/88) of the cases with <i>BMP3b</i>
methylation were also positive for <i>BMP6</i> methylation; 31% (21/67) of
cases without <i>BMP3b</i> methylation were positive for <i>BMP6</i>
methylation. This statistically significant association between concurrent
methylation of <i>BMP3b</i> and <i>BMP6</i> (<i>P</i>=0.009) indicates that the
epigenetic silencing of these genes does not occur independently in lung
cancer.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif";mso-ansi-language:
EN'>Relationship between BMP methylation and <i>k-ras</i> mutation in NSCLC </span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:EN'>We next
investigated the relationship between BMP epigenetic inactivation and <i>k-ras</i>
mutation. We previously have reported the <i>k-ras</i> mutation status of these
cases (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib17">Nelson
<i>et al</i>, 1999</a>). In the subset of cases with both <i>k-ras</i> and BMP
data, 16% (24/147) were mutated at codon 12 of the <i>k-ras</i> gene and <i>BMP3b</i>
methylation was significantly associated with <i>k-ras</i> mutation (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/table/tbl1/"
target=true>Table 1</a>, <i>P</i>&lt;0.03). Those with <i>BMP6</i> methylation
were more likely to have <i>k-ras</i> mutation, but this was not statistically
significant. However, concurrent methylation of both <i>BMP3b</i> and <i>BMP6</i>
was strongly associated with <i>k-ras</i> mutation (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/table/tbl1/"
target=true>Table 1</a>, <i>P</i>&lt;0.003).</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/table/tbl1/"
target=table><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-no-proof:yes;text-decoration:none;text-underline:none'><img border=0
width=204 height=140 id="_x0000_i1026"
src="PMC%202361658%20Table%202_files/image004.png" alt="Table 1"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/table/tbl1/"
target=table>Table 1</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'>BMP methylation and <i>k-ras</i> mutation in NSCLC</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif";mso-ansi-language:
EN'>Concurrent BMP methylation, <i>k-ras</i> mutation, and tobacco and asbestos
exposure in NSCLC </span></b></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:
EN'>k-ras</span></i><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'> mutation has previously been associated with asbestos
exposure in these patients (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib17">Nelson <i>et
al</i>, 1999</a>). In addition, pulmonary interstitial fibrosis (a condition
associated with asbestos exposure) is associated with activation of the
BMP/SMAD signalling pathway (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib13">Matsuse <i>et
al</i>, 1996</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib18">Rosendahl <i>et
al</i>, 2002</a>). <span style='background:yellow;mso-highlight:yellow'>Therefore,
we examined the relationship between tobacco use, asbestos exposure and <i>k-ras</i>
mutation, and epigenetic silencing of the BMPs (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/table/tbl2/"
target=true>Table 2</a>).</span> <span style='background:yellow;mso-highlight:
yellow'>A logistic regression analysis, controlling for histology and gender showed
that tumours with <i>k-ras</i> mutation are six-fold more likely to have
concurrent <i>BMP3/6</i> silencing (OR=6.0, 95% confidence interval (CI)
=2.0�17.9) and asbestos exposure significantly decreased the likelihood of
concurrent <i>BMP3/6</i> methylation (OR=0.2, CI 0.1�0.9; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/table/tbl2/"
target=true>Table 2</a>).</span> <span style='background:yellow;mso-highlight:
yellow'>There was no statistically significant relationship between BMP
methylation and tobacco exposure (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/table/tbl2/"
target=true>Table 2</a>).</span></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/table/tbl2/"
target=table><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-no-proof:yes;text-decoration:none;text-underline:none'><img border=0
width=204 height=137 id="_x0000_i1025"
src="PMC%202361658%20Table%202_files/image005.png" alt="Table 2"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/table/tbl2/"
target=table>Table 2</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
background:yellow;mso-highlight:yellow;mso-ansi-language:EN'>Logistic
regression modelling of BMP methylation and <i>k-ras</i> mutation in NSCLC</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:18.0pt;font-family:"Times New Roman","serif";text-transform:
uppercase;mso-ansi-language:EN'>DISCUSSION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:EN'>The BMPs are
well recognised to play multiple crucial roles in the development of diverse
tissues. They are also believed to play a role in the genesis of many tumour
types, with their inactivation allowing for dysregulated cellular
proliferation. There are multiple BMPs with overlapping substrate specificity (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib19">Stott <i>et
al</i>, 1998</a>). Our data, showing that epigenetic inactivation of <i>BMP3b</i>
(at a frequency similar to that previously reported (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib5">Dai <i>et al</i>,
2004</a>)) and <i>BMP6</i> tend to occur together in lung cancer, suggests that
in NSCLC multiple BMPs may need to be silenced in order to abrogate their
antigrowth signalling.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:EN'>Increasing
evidence shows that there is a crosstalk between TGF<i>&#946;</i>/BMP
antigrowth signalling and Ras/MAP-K progrowth signalling, and it is likely that
the interaction of these pathways is cell type and tissue specific. Some
evidence suggests that Ras inactivates SMAD signalling while other evidence
suggests that Ras activates SMAD signalling (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib10">Kretzschmar <i>et
al</i>, 1997</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib24">Yue <i>et al</i>,
1999</a>). Further, inhibitory SMADs have been shown to be upregulated in
coordination with <i>k-ras</i> mutation in epithelial cancer (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib11">Liu <i>et al</i>,
2003</a>). Although the exact relationship between BMPs and Ras in signalling
are unclear, our data are consistent with the mounting evidence that the
relationship is important in solid tumours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:EN'>The finding
that asbestos exposure is associated with a significantly different pattern of
signalling dysregulation in NSCLC supports the notion that clonal selection has
important nodal points that are influenced by the pattern of carcinogen
exposure. The current work suggests that the Ras and BMP pathways are part of a
complex network of inter-related and interacting signalling proteins where
multiple factors, including carcinogen exposure, determine the precise
character of somatic genes inactivated in this particular tumour, NSCLC. <span
style='background:yellow;mso-highlight:yellow'>In the case of BMP inactivation,
there was no apparent association of methylation silencing with tobacco
exposure.</span> <span style='background:yellow;mso-highlight:yellow'>However,
we identified an inverse relationship between asbestos exposure and BMP
methylation.</span> Asbestos exposure has been associated with cytogenetic
damage in humans (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib6">Dusinska <i>et
al</i>, 2004</a>). Hence, asbestos may be selecting for pathway inactivation
via large-scale genetic changes. For example, SMAD4, the effector protein in
the BMP pathway, has been identified as mutated and deleted in lung cancer (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib14">Nagatake <i>et
al</i>, 1996</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib1">An <i>et al</i>,
2002</a>). If asbestos were associated with induction of SMAD4 inactivation in
lung cancer, one would expect the inverse association with BMP silencing that
we have observed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:EN'>The balance
between antigrowth and progrowth signalling that is imperative for normal cell
development and homeostasis is reliant upon multiple feedback signalling
pathways. <i>k-ras</i> mutation has been described as a relatively early event
in cancer (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/#bib17">Nelson
<i>et al</i>, 1999</a>) that constitutively activates the protein leading to active
growth signalling. Our data show that the BMP pathway, which is
antiproliferative, is selected for inactivation preferentially in <i>k-ras</i>
mutant tumours in NSCLC, likely as a direct means of potentiating progrowth
signalling. Direct experimental investigation of this interaction in human
cells and a description of the effects of different carcinogens in different
tissues upon the disruption of this signalling are clearly indicated. This will
more precisely define the aetiologic effects of carcinogens (such as asbestos),
delineate the interlocking pathways that are dysregulated in solid tumours, and
potentially open avenues for prevention and treatment of these often-fatal
cancers.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:18.0pt;font-family:"Times New Roman","serif";text-transform:
uppercase;mso-ansi-language:EN'>Acknowledgments</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";mso-ansi-language:EN'>This work
was supported by CA100679, CA078609 and ES00002.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
mso-ansi-language:EN'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361658/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:18.0pt;font-family:"Times New Roman","serif";text-transform:
uppercase;mso-ansi-language:EN'>References</span></b></p>

</div>

<ul style='margin-top:0in' type=disc>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>An Q, Liu Y, Gao Y, Huang J, Fong X, Liu L, Zhang D,
     Zhang J, Cheng S. Deletion of tumor suppressor genes in Chinese non-small
     cell lung cancer. Cancer Lett. 2002;184:189�195. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12127691" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Baldus SE, Schwarz E, Lohrey C, Zapatka M, Landsberg
     S, Hahn SA, Schmidt D, Dienes HP, Schmiegel WH, Schwarte-Waldhoff I. Smad4
     deficiency in cervical carcinoma cells. Oncogene. 2004;24:810�819. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15531914" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Brubaker KD, Corey E, Brown LG, Vessella RL. Bone
     morphogenetic protein signaling in prostate cancer cell lines. J Cell
     Biochem. 2004;91:151�160. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/14689587" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Cunningham JM, Weinberg RA. Ras oncogenes in human
     tumours: identification, mechanism of activation and cooperative role in
     transformation. IARC Sci Publ. 1985;60:359�364. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/4065948" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Dai Z, Popkie AP, Zhu WG, Timmers CD, Raval A,
     Tannehill-Gregg S, Morrison CD, Auer H, Kratzke RA, Niehans G, Amatschek
     S, Sommergruber W, Leone GW, Rosol T, Otterson GA, Plass C. Bone
     morphogenetic protein 3B silencing in non-small-cell lung cancer.
     Oncogene. 2004;23:3521�3529. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15116090" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Dusinska M, Collins A, Kazimirova A, Barancokova M,
     Harrington V, Volkovova K, Staruchova M, Horska A, Wsolova L, Kocan A,
     Petrik J, Machata M, Ratcliffe B, Kyrtopoulos S. Genotoxic effects of
     asbestos in humans. Mutat Res. 2004;553:91�102. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15288536" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Haudenschild DR, Palmer SM, Moseley TA, You Z, Reddi
     AH. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin
     in prostate cancer. Cancer Res. 2004;64:8276�8284. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15548695" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Huber RM, Stratakis DF. Molecular oncology �
     perspectives in lung cancer. Lung Cancer. 2004;45 Suppl 2:S209�S213. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15552801" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Kim IY, Lee DH, Lee DK, Ahn HJ, Kim MM, Kim SJ,
     Morton RA. Loss of expression of bone morphogenetic protein receptor type
     II in human prostate cancer cells. Oncogene. 2004;23:7651�7659. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/15354178" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Kretzschmar M, Doody J, Massague J. Opposing BMP and
     EGF signalling pathways converge on the TGF-beta family mediator Smad1.
     Nature. 1997;389:618�622. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/9335504" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Liu X, Lee J, Cooley M, Bhogte E, Hartley S, Glick
     A. Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant
     conversion in a mouse model for squamous cell carcinoma. Cancer Res.
     2003;63:7760�7768. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/14633701"
     target="pmc_ext">PubMed</a>]</span><span style='mso-fareast-font-family:
     "Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Lu MM, Yang H, Zhang L, Shu W, Blair DG, Morrisey
     EE. The bone morphogenic protein antagonist gremlin regulates
     proximal�distal patterning of the lung. Dev Dyn. 2001;222:667�680. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/11748835" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Matsuse T, Ikegami A, Ohga E, Hosoi T, Oka T, Kida
     K, Fukayama M, Inoue S, Nagase T, Ouchi Y, Fukuchi Y. Expression of
     immunoreactive activin A protein in remodeling lesions associated with
     interstitial pulmonary fibrosis. Am J Pathol. 1996;148:707�713. [<a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1861725/">PMC free
     article</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/8774126"
     target="pmc_ext">PubMed</a>]</span><span style='mso-fareast-font-family:
     "Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Nagatake M, Takagi Y, Osada H, Uchida K, Mitsudomi
     T, Saji S, Shimokata K, Takahashi T. Somatic <i>in vivo</i> alterations of
     the DPC4 gene at 18q21 in human lung cancers. Cancer Res.
     1996;56:2718�2720. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/8665501"
     target="pmc_ext">PubMed</a>]</span><span style='mso-fareast-font-family:
     "Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Nakamura Y, Ozaki T, Koseki H, Nakagawara A,
     Sakiyama S. Accumulation of p27 KIP1 is associated with BMP2-induced
     growth arrest and neuronal differentiation of human neuroblastoma-derived
     cell lines. Biochem Biophys Res Commun. 2003;307:206�213. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12850001" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Nakayama K, Tamura Y, Suzawa M, Harada S, Fukumoto
     S, Kato M, Miyazono K, Rodan GA, Takeuchi Y, Fujita T. Receptor tyrosine
     kinases inhibit bone morphogenetic protein-Smad responsive promoter
     activity and differentiation of murine MC3T3-E1 osteoblast-like cells. J
     Bone Miner Res. 2003;18:827�835. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12733721" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Nelson HH, Christiani DC, Wiencke JK, Mark EJ, Wain
     JC, Kelsey KT. k-ras mutation and occupational asbestos exposure in lung
     adenocarcinoma: asbestos-related cancer without asbestosis. Cancer Res.
     1999;59:4570�4573. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/10493509"
     target="pmc_ext">PubMed</a>]</span><span style='mso-fareast-font-family:
     "Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Rosendahl A, Pardali E, Speletas M, Ten Dijke P,
     Heldin CH, Sideras P. Activation of bone morphogenetic protein/Smad
     signaling in bronchial epithelial cells during airway inflammation. Am J
     Respir Cell Mol Biol. 2002;27:160�169. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/12151307" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Stott FJ, Bates S, James MC, McConnell BB, Starborg
     M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH, Peters G. The
     alternative product from the human CDKN2A locus, p14(ARF), participates in
     a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17:5001�5014. [<a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1170828/">PMC free
     article</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/9724636"
     target="pmc_ext">PubMed</a>]</span><span style='mso-fareast-font-family:
     "Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Tamada H, Kitazawa R, Gohji K, Kitazawa S.
     Epigenetic regulation of human bone morphogenetic protein 6 gene
     expression in prostate cancer. J Bone Miner Res. 2001;16:487�496. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/11277266" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Wach S, Schirmacher P, Protschka M, Blessing M.
     Overexpression of bone morphogenetic protein-6 (BMP-6) in murine epidermis
     suppresses skin tumor formation by induction of apoptosis and
     downregulation of fos/jun family members. Oncogene. 2001;20:7761�7769. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/11753654" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Weaver M, Yingling JM, Dunn NR, Bellusci S, Hogan
     BL. Bmp signaling regulates proximal�distal differentiation of endoderm in
     mouse lung development. Development. 1999;126:4005�4015. [<a
     href="http://www.ncbi.nlm.nih.gov/pubmed/10457010" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Xu RH, Dong Z, Maeno M, Kim J, Suzuki A, Ueno N,
     Sredni D, Colburn NH, Kung HF. Involvement of Ras/Raf/AP-1 in BMP-4
     signaling during <i>Xenopus</i> embryonic development. Proc Natl Acad Sci
     USA. 1996;93:834�838. [<a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC40143/">PMC free article</a>]
     [<a href="http://www.ncbi.nlm.nih.gov/pubmed/8570644" target="pmc_ext">PubMed</a>]</span><span
     style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></li>
 <li class=MsoNormal style='line-height:normal;mso-list:l1 level1 lfo3;
     tab-stops:list .5in'><span lang=EN style='font-size:12.0pt;font-family:
     "Times New Roman","serif";mso-fareast-font-family:"Times New Roman";
     mso-ansi-language:EN'>Yue J, Frey RS, Mulder KM. Cross-talk between the
     Smad1 and Ras/MEK signaling pathways for TGFbeta. Oncogene.
     1999;18:2033�2037. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/10208426"
     target="pmc_ext">PubMed</a>]</span><span style='mso-fareast-font-family:
     "Times New Roman"'><o:p></o:p></span></li>
</ul>

<p class=MsoNormal>&nbsp;</p>

</div>

</body>

</html>
